Special Offer: Get 50% off your first 2 months when you do one of the following
Personalized offer codes will be given in each session
Share This Webinar
To invite people, share this page:
                                           
About This Webinar

Sponsored by: Biomodels, LLC

The microbiome represents a novel and exciting therapeutic target, with a critical function in the maintenance of immune homeostasis, and a dysfunctional microbiome is linked to a diverse range of disease states. Moreover, accumulating data suggests that individual-to-individual microbiome heterogeneity can impact the efficacy of small-molecules and biologics. Additionally, Phase III clinical success has been reported with an oral microbiome-based therapy targeting C. difficile infection, further supporting continued microbiome R&D investment. As the role for the microbiome in health and disease is increasingly appreciated, understood, and commercialized, it’s critical to consider the microbiome in your preclinical research.

This webinar will discuss approaches and considerations that are applicable to both disease phenotype targeting and biologic/small molecule efficacy targeting strategies in preclinical microbiome research. Discussed approaches will include fecal microbial transplant, “bugs as drugs,” antibiotic pre-treatment paradigms, and how germ-free mice can be used to support a microbiome research program. We will provide examples of experimental systems designed to address proof-of-concept, mechanism of action, and efficacy questions. The webinar will conclude with a discussion of several microbiome-focused study designs and data sets.

Learning Objectives:
1) Provide an overview of major areas of preclinical microbiome research and common questions
2) Discuss Biomodels’ approach to novel microbiome strategies in preclinical animal modeling
3) Present examples of microbiome focused research concepts, study designs, and outcomes

Privacy Policy

Categories:
SCIENCE & TECH
When: Tue, Sep 27, 2022 · 11:00 AM · Eastern Time (US & Canada)
Duration: 1 hour
Language: English
Who can attend? Everyone
Webinar ID: 3535e30c20d0
Dial-in available? (listen only): No
Featured Presenters
Webinar hosting presenter
Associate Director of Research Operations, Biomodels, LLC
Dr. Parello joined Biomodels in 2016 as an Associate Scientist after completing her post-doctoral studies in the Department of Pathology at the University of Massachusetts Medical School where she focused on the development of a clinically relevant, humanized murine model of Experimental Autoimmune Encephalomyelitis (EAE) as a conduit for assessing interventions for multiple sclerosis (MS). Caitlin received her PhD from Boston University School of Medicine in 2014, where she adapted two murine models of Shiga Toxin 2- induced kidney injury, and was an NIH- funded pre-doctoral fellow and Russek award winner. At Biomodels, Caitlin has successfully combined her background in adaptive immunity and murine model development and has incorporated both into assisting clients in addressing questions around product development in areas which include the interaction of the microbiome and immune system, the potential dysbiosis mediating inflammatory/autoimmune disorders, and determining if restoration of eubiosis can be therapeutic for such disorders. Dr. Parello led the establishment of Biomodels’ germ-free/gnotobiotic murine isolator facility and serves as the lead scientist on microbiome-related studies.
Webinar hosting presenter
Scientific Program Manager, Microbiome Discovery Solutions, Taconic Biosciences
Veronica Peterson has 8 years’ experience in the microbiome field. Her PhD research focused on the microbiome-gut-brain axis. This research was conducted under the supervision of Prof. John F. Cryan in association with APC Microbiome Ireland. Postdoctoral work focused on microbiome analysis methods with an emphasis on bioinformatics and biostatistics. Throughout her career Veronica has had the opportunity to collaborate on many exciting topics including addiction and reward-learning, neurodegenerative disorders, characterization of novel microbes in deep sea fish, and bacteriophage dynamics in the gut microbiome, among many others.